Human papillomavirus prevalence among indigenous and non-indigenous Australian women prior to a national HPV vaccination program
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Indigenous women in Australia have a disproportionate burden of cervical cancer despite a national cervical screening program. Prior to introduction of a national human papilloma virus (HPV) vaccination program, we determined HPV genotype prevalence by Indigenous status and residence in remote areas. METHODS: We recruited women aged 17 to 40 years presenting to community-based primary health services for routine Pap screening across Australia. A liquid-based cytology (LBC) cervical specimen was tested for HPV DNA using the AMPLICOR HPV-DNA test and a PGMY09/11-based HPV consensus PCR; positive specimens were typed by reverse hybridization. We calculated age-adjusted prevalence by weighting to relevant population data, and determined predictors of HPV-DNA positivity by age, Indigenous status and area of residence using logistic regression. RESULTS: Of 2152 women (655 Indigenous), prevalence of the high-risk HPV genotypes was similar for Indigenous and non-Indigenous women (HPV 16 was 9.4% and 10.5%, respectively; HPV 18 was 4.1% and 3.8%, respectively), and did not differ by age group. In younger age groups, the prevalence of other genotypes also did not differ, but in those aged 31 to 40 years, HPV prevalence was higher for Indigenous women (35% versus 22.5%; P < 0.001), specifically HPV clades α5 (OR = 2.1, 95% CI 1.1 to 4.3) and α7, excluding type 18 (OR 1.9, 95% CI 1.1 to 3.3). In multivariate analysis, detection of any HPV genotype was strongly associated with smoking and Pap-test abnormalities, with both risk factors more common among Indigenous women. CONCLUSION: Although we found no difference in the prevalence of HPV16/18 among Australian women by Indigenous status or, for Indigenous women, residence in remote regions, differences were found in the prevalence of risk factors and some other HPV genotypes. This reinforces the importance of cervical screening as a complement to vaccination for all women, and the value of baseline data on HPV genotype prevalence by Indigenous status and residence for the monitoring of vaccine impact.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
de Sanjose, S., Quint, W. G., Alemany, L., Geraets, D. T., Klaustermeier, J. E., Lloveras, B., Tous, S., Felix, A., Bravo, L. E., Shin, H.-R., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70230-8 · Cited by 2,728
Self-citationQuadrivalent vaccine against human papillomavirus to prevent anogenital diseases
Garland, S. M., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Harper, D. M., Leodolter, S., Tang, G. W. K., Ferris, D. G., Steben, M., Bryan, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061760 · Cited by 1,886 · cited 1×
“Given the early results of Phase 3 vaccine trials of a bivalent [4] and quadrivalent vaccine [5,6], which have * Correspondence: suzanne.”
BackgroundSelf-citationde Sanjosé, S., Diaz, M., Castellsagué, X., Clifford, G., Bruni, L., Muñoz, N., & Bosch, F. X. (2007) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(07)70158-5 · Cited by 1,669
Paavonen, J., Naud, P., Salmerón, J., Wheeler, C., Chow, S.-N., Apter, D., Kitchener, H., Castellsague, X., Teixeira, J., Skinner, Sr., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61248-4 · Cited by 1,655
Self-citationImproved Amplification of Genital Human Papillomaviruses
Gravitt, P. E., Peyton, C. L., Alessi, T. Q., Wheeler, C. M., Coutlée, F., Hildesheim, A., Schiffman, M. H., Scott, D. R., & Apple, R. J. (2000) · Journal of Clinical Microbiology · doi:10.1128/jcm.38.1.357-361.2000 · Cited by 1,137 · cited 1×
“As this test detects only 13 HR HPV types, all samples testing negative for HR HPV by this test were also tested to exclude presence of other types, using a 20 μl aliquot of extracted DNA in a PGMY09/11-based HPV consensus PCR assay [25].”
Method
Cited by
Garland, S. M., Kjaer, S. K., Muñoz, N., Block, S. L., Brown, D. R., DiNubile, M. J., Lindsay, B. R., Kuter, B. J., Perez, G., Dominiak-Felden, G., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw354 · Cited by 497
Self-citationTabrizi, S. N., Brotherton, J. M. L., Kaldor, J. M., Skinner, S. R., Liu, B., Bateson, D., McNamee, K., Garefalakis, M., Phillips, S., Cummins, E., et al. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70841-2 · Cited by 301
Self-citationFall in Human Papillomavirus Prevalence Following a National Vaccination Program
Tabrizi, S. N., Brotherton, J. M. L., Kaldor, J. M., Skinner, S. R., Cummins, E., Liu, B., Bateson, D., McNamee, K., Garefalakis, M., & Garland, S. M. (2012) · Journal of Infectious Diseases · doi:10.1093/infdis/jis590 · Cited by 264
Self-citationWendland, E. M., Villa, L. L., Unger, E. R., Domingues, C. M., Benzaken, A. S., POP-Brazil Study Group, Maranhão, A. G. K., Kops, N. L., Bessel, M., Caierão, J., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-61582-2 · Cited by 72
Garland, S. M., Cornall, A. M., Brotherton, J. M. L., Wark, J. D., Malloy, M. J., & Tabrizi, S. N. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.04.080 · Cited by 50
Self-citation
Metadata
- Authors
- the WHINURS study group, Garland, S. M., Brotherton, J. M., Condon, J. R., McIntyre, P. B., Stevens, M. P., Smith, D. W., & Tabrizi, S. N.
- Venue
- BMC Medicine
- Published
- 2011-09-13
- Volume
- 9
- Issue
- 1
- Pages
- 104-104
- ISSN
- 1741-7015 (ISSN-L)
- OpenAlex
- W2140338677
- Cited by
- 80
- References
- 5
- FWCI
- 6.92
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Human papillomavirus prevalence among indigenous and non-indigenous Australian women prior to a national HPV vaccination program. https://app.cochat.ai/papers/10.1186/1741-7015-9-104
- The paper
- the WHINURS study group, Garland, S. M., Brotherton, J. M., Condon, J. R., McIntyre, P. B., Stevens, M. P., Smith, D. W., & Tabrizi, S. N. (2011). Human papillomavirus prevalence among indigenous and non-indigenous Australian women prior to a national HPV vaccination program. BMC Medicine. https://doi.org/10.1186/1741-7015-9-104
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.